A Multicentre Primary & Booster Vaccination Study of GSK Biologicals' Hib-MenCY-TT Conjugate Vaccine vs ActHIB & MenC Conjugate Licensed Vaccine When Given According to the 2-4-6 Month Schedule to Healthy Infants With Booster Dose at 12 to 15 Months

Trial Profile

A Multicentre Primary & Booster Vaccination Study of GSK Biologicals' Hib-MenCY-TT Conjugate Vaccine vs ActHIB & MenC Conjugate Licensed Vaccine When Given According to the 2-4-6 Month Schedule to Healthy Infants With Booster Dose at 12 to 15 Months

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2015

At a glance

  • Drugs Hib-meningococcal vaccine groups C and Y conjugate (Primary) ; Hib vaccine conjugate; Meningococcal vaccine group C conjugate
  • Indications Haemophilus infections; Meningococcal group C infections; Meningococcal group Y infections; Pneumococcal infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 19 Jul 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
    • 19 Jul 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
    • 02 May 2010 Pooled results, combined with a US study (see trial profile 700037873), presented as a poster at the 2010 Annual Meeting of the Pediatric Academic Societies (PAS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top